Exploring Catalysis in API Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Exploring Catalysis in API Synthesis
Chemocatalysis and biocatalysis are important elements of an effective strategy for improving yield and stereoselectivty.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 42-46

Systems catalysis

The NRSC-Catalysis program is also advancing a systems approach to catalysis, which analyzes functional catalytic systems in which multiple molecular processes are combined and regulated to carry out a catalytic operation. The goal of systems catalysis is to combine homogeneous, heterogeneous, and biocatalytic methods. A potential advantage of a systems approach to catalysis is to create "one-pot" multiple component catalyst systems for multistep synthesis. Most traditional synthesis is performed sequentially by ending one reaction step and then proceeding to the next reaction step, which may involve solvent and temperature swaps, liquid–liquid extractions, product crystallization, chromatographic purification, distillation, the addition or removal of protecting groups, and the addition and removal of reagents and catalysts. A systems approach would allow for a more directed way of developing catalytic reaction sequences and one-pot multicomponent catalyst systems (5).

Asymmetric synthesis

Strategies in asymmetric synthesis is an area of ongoing interest, particularly in the production of pharmaceutical compounds. In 2009, researchers from the University of Bristol in the United Kingdom and the University of Gothenburg in Sweden reported findings from their work in palladium-based asymmetric catalysis. The key finding was structural and mechanistic information on Trost modular ligands (TMLs), which combine with palladium to form catalysts. TML-Pd catalysts are widely used in allylic substitution reactions (8, 9). Their new model involved two regiochemically distinct (NH) and (CO) locations for nucleofuge or nucleophile binding, which may have broad utility for understanding the selectivity in asymmetric allylic alkylation reactions catalyzed by select palladium complexes and related ligands (8, 9).

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
.

References

1. J. Wassenaar et al., Nat. Chem. 2 (5), 417–421 (2010).

2. S. Borman, Chem. & Eng. News 88 (14), 7 (2010).

3. S. Ritter, N. Becker, and T. Blair, Chem. & Eng. News 87 (51), 35–39 (2009).

4. S.L. Desset and D.J. Cole-Hamilton, Angew. Chem., Int. Ed. Engl. 48 (8), 1472–1474 (2009).

5. NRSC-Catalysis, Future Perspectives in Catalysis (Amsterdam), http://www.nrsc-catalysis.nl/files/media/scientific_reports/Future_perspectives_in_Catalysis.pdf, accessed Apr. 5, 2010.

6. D. Toste et al., Nat. Chem. 2 (1), 36–41 (2010).

7. M. Jacoby, Chem. & Eng. News 87 (49), 10 (2009).

8. S. Borman, Chem. & Eng. News 87 (24), 31–33 (2009).

9. G.C. Lloyd. J. Am. Chem. Soc ., 131 (8), 9945–9957 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here